This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Drug: LY2503029
Administered orally.
Drug: LY3023414
Administered orally.
Inclusion Criteria:
- To be eligible patients must be currently receiving benefit in a concluded Lilly study
for a compound that has opened an addendum in the continued access protocol.
Exclusion Criteria:
- Patients must not be concurrently enrolled in any other type of medical research
judged not to be scientifically or medically compatible with this study.
UCLA Medical Center
Torrance, California, United States
Fort Wayne Oncology & Hematology
Fort Wayne, Indiana, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST), Study Director
Eli Lilly and Company